Previous 10 | Next 10 |
Tracon (NASDAQ: TCON ): Q2 GAAP EPS of -$0.21 misses by $0.02 . More news on: TRACON Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration through our license to Santen Pha...
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharma...
Deals and Financings United Family Healthcare, a chain of nine private China hospitals, agreed to be acquired by New Frontier Corp. (NFC), a public investment vehicle, at an expected value of $1.44 billion. UFH is currently owned by TPG and Fosun Pharma (SHA: 600196; HK: 2196). It is one...
SHANGHAI, China and SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focusing on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and auto...
SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration through our license to Santen Pha...
SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharma...
Phase 1 Data Published in ASCO Proceedings Determined the Recommended Phase 2 Dose Additional Cohort of Patients with a Specific Androgen Receptor Point Mutation Added to Ongoing Phase 2 Study Phase 2 Data Expected in 2 nd half 2020; Potential for $45 Million Opt-in Payment from ...
Phase 1 Data Published in ASCO Proceedings Determined the Recommended Phase 2 Dose Additional Cohort of Patients with a Specific Androgen Receptor Point Mutation Added to Ongoing Phase 2 Study Phase 2 Data Expected in 2 nd half 2020; Potential for $45 Million Opt-in Payment from ...
SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen Pharmaceutical Co. Ltd., wet age‐...
News, Short Squeeze, Breakout and More Instantly...
TRACON Pharmaceuticals Inc. Company Name:
TCON Stock Symbol:
OTCMKTS Market:
TRACON Pharmaceuticals Inc. Website:
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R....
A look at the top 10 most actives in the United States Yoshitsu Co. Ltd (TKLF) rose 103.4% to $0.623 on volume of 309,019,720 shares Maxeon Solar Technologies Ltd. (MAXN) rose 11.2% to $0.2524 on volume of 226,231,487 shares NVIDIA Corporation (NVDA) fell 1.6% to $126.36 on volume of 208,...
A look at the top 10 most actives in the United States American Rebel Holdings Inc. (AREB) rose 60.3% to $0.83355 on volume of 56,112,820 shares DatChat Inc. (DATS) rose 71.2% to $1.78 on volume of 33,845,116 shares Autonomix Medical Inc. (AMIX) rose 97.4% to $1.22 on volume of 33,054,234...